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As we near the New Millennium, Tropical Medicine faces new opportunities and
challenges. In the USA, there is a growing appreciation that Global Health affects everyone,
that infectious diseases are "emerging and re-emerging", and that the US is a leader in
science and technology with global leadership responsibilities. This presentation will be
divided into three parts: 1) identifying major challenges facing tropical medicine; 2) a dis-
cussion of general strategies which NIAID is developing to meet these challenges; and 3) a
description of changes in the NIAID International Collaboration in Infectious Disease
Research (ICIDR) designed to meet these challenges and take full advantage of scientific
opportunities in a responsible fashion.
The challenges are created by the fact that the revolutions in immunology, molecular
biology, and information systems have created a situation in which investment in basic
sciences is paying dividends in the development of unprecedented numbers of new or im-
proved diagnostic test, drugs, and vaccine candidates for infectious diseases. When indus-
trialized and developing countries share infectious disease problems (e.g. acute respiratory
infections, enteric infections), the industrialized countries invest heavily in research while
developing countries bear the greater -burden of disease. When a disease occurs
predominately or exclusively in a developing country, industrialized countries often do not
invest heavily in research and the endemic countries have limited resources and capacity to
carry out research to develop treatment or prevention products for their unique disease con-
ditions.
To overcome these problems, NIAID is developing a strategy to: 1) promote linkages
between industrialized research institutions and counterparts in developing countries; 2)
promoting collaboration which takes a broad, long-term perspective rather than focusing on
the immediate research proposal; 3) involve scientists from developing countries in the basic
research and discovery process leading to the discovery of new drugs and vaccines; 4) in-
volving scientists from industrialized countries in field and community-based research; 5)
promoting global partnerships and networks to work together on specific pathogens; 6) en-
hance the capacity of developing countries to carry out independent research on their priority
endemic infectious diseases; and 7) generate support from development and lending agencies
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and industry to develop, license, and produce regional diagnostic tests, drugs, and vaccines.
Over the years, NIAID, has developed programs which link US biomedical research
institutions with partners in developing or resource poor countries to carry out collaborative
research in tropical infectious diseases (ICIDR Program; HIV/AIDS (HIVNET Program);
tuberculosis (Tuberculosis Research Center); and, most recently, Emerging and Re-Emerging
Infectious Diseases. The presentation will use the recent modifications in the ICIDR Program
to illustrate attempts to implement this strategy and tie the ICIDR participants into a con-
sorted effort to identify new and re-emerging infectious diseases and mount a rapid response
by the research community to new or unexpected public health problems.
